Mastocytosis: current concepts in diagnosis and treatment - PubMed (original) (raw)

Review

. 2002 Dec;81(12):677-90.

doi: 10.1007/s00277-002-0575-z. Epub 2002 Nov 29.

Affiliations

• PMID: 12483363
• DOI: 10.1007/s00277-002-0575-z

Review

Mastocytosis: current concepts in diagnosis and treatment

L Escribano et al. Ann Hematol. 2002 Dec.

Abstract

Mastocytosis consists of a group of disorders characterized by a pathologic increase in mast cells in tissues including skin, bone marrow, liver, spleen, and lymph nodes. Mastocytosis is a rare disease. Because of this, general practitioners have limited exposure to its clinical manifestations, diagnosis, classification, and management. Diagnosis of mastocytosis is suspected on clinical grounds and is established by histopathologic examination of involved tissues such as skin and bone marrow. The most common clinical sign of mastocytosis is the presence of typical skin lesions of urticaria pigmentosa. Most patients experience symptoms related to mast cell mediator release, and prevention of the effects of these mediators on tissues constitutes the major therapeutic goal in the management of mastocytosis. Despite recent advances in knowledge about the pathophysiology, diagnosis, and classification of mastocytosis, a curative treatment for mastocytosis does not now exist. Management of patients within all categories of mastocytosis includes: (1) a careful counseling of patients (parents in pediatric cases) and care providers, (2) avoidance of factors triggering acute mediator release, (3) treatment of acute mast cell mediator release, (4) treatment of chronic mast cell mediator release, and if indicated (5) an attempt to treat organ infiltration by mast cells. The goal of this manuscript is to provide an overview of the mediators produced and released by mast cells, the diagnostic criteria for the different variants of mastocytosis, and the treatment options currently available.

PubMed Disclaimer

Similar articles

• [Guidelines for the diagnosis, treatment and management of mastocytosis].
  De la Hoz B, González de Olano D, Alvarez I, Sánchez L, Núñez R, Sánchez I, Escribano L. De la Hoz B, et al. An Sist Sanit Navar. 2008 Jan-Apr;31(1):11-32. An Sist Sanit Navar. 2008. PMID: 18496577 Review. Spanish.
• [Mastocytosis, classification, biological diagnosis and therapy].
  Arock M. Arock M. Ann Biol Clin (Paris). 2004 Nov-Dec;62(6):657-69. Ann Biol Clin (Paris). 2004. PMID: 15563424 Review. French.
• [Systemic mastocytosis. A review of current diagnostic and therapeutic approaches].
  Pari F, Zamagni MD, Carnevali C, Pagani M, Rabbi C, Cantore M, Cavazzini G, Aitini E, Smerieri F. Pari F, et al. Recenti Prog Med. 1999 Mar;90(3):169-72. Recenti Prog Med. 1999. PMID: 10228358 Review. Italian.
• Biology, classification and treatment of human mastocytosis.
  Valent P. Valent P. Wien Klin Wochenschr. 1996;108(13):385-97. Wien Klin Wochenschr. 1996. PMID: 8766423 Review.
• Mastocytosis: state of the art.
  Horny HP, Sotlar K, Valent P. Horny HP, et al. Pathobiology. 2007;74(2):121-32. doi: 10.1159/000101711. Pathobiology. 2007. PMID: 17587883 Review.

Cited by

• Mastocytosis demystified.
  Veitch S, Radia DH. Veitch S, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):396-406. doi: 10.1182/hematology.2023000505. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066855 Review.
• CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells.
  Schneeweiss-Gleixner M, Filik Y, Stefanzl G, Berger D, Sadovnik I, Bauer K, Smiljkovic D, Eisenwort G, Witzeneder N, Greiner G, Hoermann G, Schiefer AI, Schwaab J, Jawhar M, Reiter A, Sperr WR, Arock M, Valent P, Gleixner KV. Schneeweiss-Gleixner M, et al. Cancers (Basel). 2022 Jun 23;14(13):3070. doi: 10.3390/cancers14133070. Cancers (Basel). 2022. PMID: 35804842 Free PMC article.
• Mastocytosis presenting with mast cell-mediator release-associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features.
  Rama TA, Morgado JM, Henriques A, Escribano L, Alvarez-Twose I, Sanchez-Muñoz L, Moreira A, Romão J, Órfão A, Matito A. Rama TA, et al. Clin Transl Allergy. 2022 Mar;12(3):e12132. doi: 10.1002/clt2.12132. Clin Transl Allergy. 2022. PMID: 35344302 Free PMC article.
• Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells.
  Mancini M, Monaldi C, De Santis S, Rondoni M, Papayannidis C, Sartor C, Curti A, Bruno S, Cavo M, Soverini S. Mancini M, et al. Cancers (Basel). 2022 Jan 31;14(3):738. doi: 10.3390/cancers14030738. Cancers (Basel). 2022. PMID: 35159005 Free PMC article.
• Systemic Mastocytosis: Multidisciplinary Approach.
  Zanotti R, Tanasi I, Crosera L, Bonifacio M, Schena D, Orsolini G, Mastropaolo F, Tebaldi M, Olivieri E, Bonadonna P. Zanotti R, et al. Mediterr J Hematol Infect Dis. 2021 Nov 1;13(1):e2021068. doi: 10.4084/MJHID.2021.068. eCollection 2021. Mediterr J Hematol Infect Dis. 2021. PMID: 34804442 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer